You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

56 search results for: pediatric

ADVENT On Air | Defining AD in <b>Pediatric</b> Patients

Podcast

ADVENT On Air | Defining AD in Pediatric Patients

15 min

Dermatology

Learn more about the journey of pediatric patients with AD in this conversation between Drs. Lisa Swanson and Weily Soong.

ADVENT On Air | Clinical Perspective on <b>Pediatric</b> Patients With Atopic Dermatitis

Podcast

ADVENT On Air | Clinical Perspective on Pediatric Patients With Atopic Dermatitis

15 min

Dermatology

Listen to the expert perspectives of Drs. Lisa Swanson and Weily Soong on clinical considerations in pediatric patients with atopic dermatitis.

Type 2 Inflammation Mediates Severe Asthma in <b>Pediatric</b> Patients

expert video

Type 2 Inflammation Mediates Severe Asthma in Pediatric Patients

19 min

Pulmonology

Dr. Leonard Bacharier discusses how type 2 inflammation underlies the pathophysiology of pediatric severe asthma and contributes to burden.

How Can FeNO Support the Management of <b>Pediatric</b> Asthma?

expert video

How Can FeNO Support the Management of Pediatric Asthma?

2 min

Pulmonology

Dr. Michael Blaiss discusses the importance of measuring FeNO in pediatric asthma patients.

Type 2 Inflammation Underpins <b>Pediatric</b> Severe Asthma

Infographic

Type 2 Inflammation Underpins Pediatric Severe Asthma

5 min

Pulmonology

Learn about the role type 2 inflammation plays in the burden and pathophysiology of severe asthma in pediatric patients.

Burdens Experienced by <b>Pediatric</b> Asthma Patients and Their Caregivers

expert video

Burdens Experienced by Pediatric Asthma Patients and Their Caregivers

3 min

Pulmonology

Drs. Michael Blaiss and Bob Geng discuss the burdens experienced by pediatric severe asthma patients and their caregivers.

FeNO: A Biomarker of Type 2 Inflammation in <b>Pediatric</b> Asthma Patients

Infographic

FeNO: A Biomarker of Type 2 Inflammation in Pediatric Asthma Patients

5 min

Pulmonology

Learn about the role of FeNO as a noninvasive test to identify type 2 inflammation in pediatric patients with asthma

Importance of Lung Function Assessment in <b>Pediatric</b> Asthma Patients

videoanimation

Importance of Lung Function Assessment in Pediatric Asthma Patients

3 min

Pulmonology

Review the burden associated with lung function decline in pediatric patients with severe asthma, and the value of clinical lung function assessments.

Expert Insights: Importance of Lung Function Assessment in <b>Pediatric</b> Asthma Patients

expert video

Expert Insights: Importance of Lung Function Assessment in Pediatric Asthma Patients

2 min

Pulmonology

Dr. Michael Blaiss describes the importance of lung function assessment in pediatric asthma management

ADVENT On Air | Getting to the Diagnosis of AD in <b>Pediatric</b> Patients

Podcast

ADVENT On Air | Getting to the Diagnosis of AD in Pediatric Patients

15 min

Dermatology

Learn more about the journey to diagnosis for pediatric patients with AD in this conversation between Drs. Lisa Swanson and Weily Soong.

Explore the Global Burden of <b>Pediatric</b> AD (PEDISTAD)

interactivity

Explore the Global Burden of Pediatric AD (PEDISTAD)

15 min

Dermatology

This interactive tool allows you to explore the global burden of AD in pediatric patients <12 years from the PEDISTAD Study.

Type 2 Inflammation Is a Significant Driver of <b>Pediatric</b> Severe Asthma

Infographic

Type 2 Inflammation Is a Significant Driver of Pediatric Severe Asthma

5 min

Pulmonology

Learn about the role of type 2 inflammation in the burden and pathophysiology of severe asthma in pediatric patients

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: JapanChange country/region